Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(21):1804-1805; doi:10.1093/jnci/91.21.1804
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 21, 1804-1805, November 3, 1999
© 1999 Oxford University Press

NEWS

Advances in Treatment for Eye Cancer Bring Visible Benefits

Tom Reynolds

Patients with ocular cancers used to have little choice but to sacrifice the eye for a chance to save their life. But treatment innovations have allowed many to preserve their eyes and, in some cases, vision.

Removal of the eyeball, known as enucleation, is still commonly used for large tumors. But radio-, cryo-, and thermal therapies have expanded the arsenal over the past 2 decades.

While a variety of cancers — breast, lung, lymphomas, leukemias — occasionally metastasize to the eye, melanoma is the most common primary eye cancer in adults. Most melanomas occur in the area of the eye called the uvea, consisting of the iris, ciliary body, and choroid. Iris tumors are the least threatening, in part because unlike other uveal tumors they are visible, small in size, and usually are . . . [Full Text of this Article]

Palladium-103 Radiotherapy

High-Temperature Therapy

Genetic Testing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?